Open AccessAstragaloside IV inhibited the activity of CYP 1 A 2 in liver microsomes and influenced theophylline pharmacokinetics in rats
Author(s) -
Zhang YanHui,
Zhang YouJin,
Guo YanLei,
Li WenJuan,
Yu Chao
Publication year - 2013
Publication title -
journal of pharmacy and pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.745
H-Index - 118
eISSN - 2042-7158
pISSN - 0022-3573
DOI - 10.1111/j.2042-7158.2012.01579.x
Subject(s) - theophylline , phenacetin , cyp1a2 , pharmacology , pharmacokinetics , in vivo , microsome , chemistry , caffeine , in vitro , medicine , biochemistry , biology , microbiology and biotechnology
Objectives With the growing popularity of herbal and natural medicinal products, attention has turned to possible interactions between these products and pharmaceutical drugs. In this study, we examined whether astragaloside IV ( AGS ‐ IV ) could inhibit the activity of CYP 1 A 2 in rat liver microsomes in vitro and in vivo . Methods The effect of AGS ‐ IV on CYP 1 A 2 activity was investigated using probe substrates: phenacetin in vitro and theophylline in vivo . Phenacetin was incubated in rat liver microsomes with or without AGS ‐ IV , and the mechanism, kinetics and type of inhibition were determined. The inhibitory effect of AGS‐IV on CYP 1 A 2 activity in rats was also determined using theophylline in vivo . The pharmacokinetics of theophylline were observed after a single or week‐long treatment with AGS ‐ IV . Key findings AGS ‐ IV was found to be a competitive inhibitor with a K i value of 6.29 μ m in vitro . In the multiple‐pretreatment rat group, it was found to have a significantly higher area under the concentration–time curve ( AUC ) for theophylline, as well as a lower apparent oral total body clearance value ( CL / F ). In contrast, no significant difference in metabolism of theophylline was found for the single pretreatment group. Conclusions These findings suggest that AGS ‐ IV is a potent inhibitor of CYP 1 A 2. This work offers a useful reference for the reasonable and safe use of clinically prescribed herbal or natural products to avoid unnecessary herb–drug interactions.